drugset / Trial / NCT03997474
ATL001 in Patients With Metastatic or Recurrent Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with metastatic or recurrent melanoma.
Timeline
- Start
- 2019-08-15
- Primary completion
- 2024-09-03
- Completion
- 2024-09-03
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATL001 | Cell therapy | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | — |